Systemic treatment for inoperable pancreatic adenocarcinoma: review and update / 癌症

There have been many clinical trials conducted to evaluate novel systemic regimens for unresectable pancreatic cancer. However, most of the trial results were negative, and gemcitabine monotherapy has remained the standard systemic treatment for years. A number of molecular targeted agents, including those against epidermal growth factor receptor and vascular endothelial growth factor receptors, have also been tested. In recent years, there have been some breakthroughs in the deadlock: three regimens, namely gemcitabine-erlotinib, FOLFIRINOX, and gemcitabine-nab-paclitaxel, have been shown to prolong the overall survival of patients when compared with gemcitabine monotherapy. In addition, emerging data suggested that the membrane protein human equilibrative nucleotide transporter 1 is a potential biomarker with which to predict the efficacy of gemcitabine. Here we review the literature on the development of systemic agents for pancreatic cancer, discuss the current choices of treatment, and provide future directions on the development of novel agents.

Complicaciones de los implantes faciales con fines estéticos / Complications for the application implants for aesthetic purposes

Las sustancias para implantes faciales se han utilizado desde los años 60. La introducción de nuevos materiales y las crecientes complicaciones por tratamientos estéticos determinan que estos pacientes consulten al dermatólogo. Presentamos cuatro pacientes de sexo femenino, con edades que van de los 51 a 88 años, que consultaron por presentar infiltraciones granulomatosas persistentes en distintas áreas de la cara, correspondientes a zonas de implantes efectuados para el relleno de arrugas. Estas manifestaciones se presentaron uno a diez años después de la aplicación de los implantes. Los hallazgos histopatológicos distintivos de cada material nos orientaron hacia el diagnóstico correcto de la sustancia inyectada